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Optogenetica b s t r a c t
Chronic pain and epilepsy together affect hundreds of millions of people worldwide. While tradi-
tional pharmacotherapy provides essential relief to the majority of patients, a large proportion
remains resistant, and surgical intervention is only possible for a select few. As both disorders are
characterised by neuronal hyperexcitability, manipulating the expression of the most direct modu-
lators of excitability – ion channels – represents an attractive common treatment strategy. A num-
ber of viral gene therapy approaches have been explored to achieve this. These range from the up- or
down-regulation of channels that control excitability endogenously, to the delivery of exogenous
channels that permit manipulation of excitability via optical or chemical means. In this review
we highlight the key experimental successes of each approach and discuss the challenges facing
their clinical translation.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Chronic pain and epilepsy represent major health concerns,
together affecting hundreds of millions of people worldwide at a
cost to the global economy of hundreds of billions of dollars
[1,2]. In Europe, it is estimated that 0.6–0.7% of the general popu-
lation suffers from epilepsy [3], and up to 20% will experience
chronic pain at some point in their lives [4]. Despite the impressive
array of drugs available to treat these disorders, a signiﬁcant pro-
portion of patients remains resistant to traditional pharmacother-
apy; 25% of epilepsies are refractory in nature [5], and as many as
two-thirds of chronic pain sufferers are dissatisﬁed with treatment
efﬁcacy [6]. Refractoriness is not the only concern. Many
antiepileptic and analgesic drugs elicit a range of unpleasant side
effects that place restrictive limits on dosing [7,8], and opioid
agents used to treat more severe forms of chronic pain are at high
risk of abuse [9]. Because surgical intervention is only possible in a
small number of cases [10,11], there is a pressing need to develop
therapeutic alternatives.
One such alternative is gene therapy, which involves the
long-term introduction, overexpression or knockdown of particu-
lar genes for therapeutic purposes. In most cases thesemanipulations take advantage of the natural infection and
genome-editing properties of viruses. Viral vectors are engineered
to encode the therapeutic genes or gene-editing constructs under
the control of promoter elements that target their expression to
speciﬁc cell types. As such, gene therapy theoretically provides
what traditional pharmacotherapy cannot: a long-lasting interven-
tion delivered to a pre-determined population of target cells.
Though plagued by a number of early setbacks [12–14], gene ther-
apy now displays considerable promise for the treatment of a num-
ber of neurological disorders [15,16].
Neuronal hyperexcitability is a common feature of epilepsy and
chronic pain. In epilepsy, hyperexcitability emerges from a range of
pathological alterations that shift the excitation-inhibition balance
within neuronal networks, leading to the generation of sponta-
neous, recurrent seizures [17–19]. These alterations include
(among others) the death of GABAergic inhibitory interneurons
and loss of GABAergic synaptic terminals [20,21], the strengthen-
ing of excitatory synaptic transmission by axonal sprouting
[22,23], changes in the release and/or re-uptake of excitatory or
inhibitory neurotransmitters [24,25], and changes in the type,
number, distribution and activation properties of particular ion
channels or neurotransmitter receptors [26–28]. Neuronal hyper-
excitability in chronic pain can also have multiple underlying
causes. These are often grouped according to the type of chronic
pain they produce. ‘‘Nociceptive’’ or ‘‘inﬂammatory’’ chronic pain
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tisation of primary nociceptive afferents during ongoing tissue
injury [29,30]. In ‘‘neuropathic’’ chronic pain, the culprit is damage
to nociceptive neural pathways; accompanying changes in gene
expression can lead to ectopic action potential (AP) generation that
long outlasts the original nerve injury [31,32]. In both types of
chronic pain, initial increases in excitability may be maintained
and even ampliﬁed by maladaptive strengthening of transmission
across central synapses in the ascending nociceptive pathway, a
phenomenon termed central sensitisation [33,34].
Despite their immensely different aetiologies, because chronic
pain and epilepsy are both characterised by neuronal hyperex-
citability, and because the mechanisms underlying excitability
are conserved across a broad range of neurons, any manipulation
capable of dampening neuronal ﬁring might prove therapeutically
efﬁcacious in the treatment of both disorders. As the most direct
modulators of cellular excitability, ion channels represent a partic-
ularly attractive target in this regard. Guided by extensive func-
tional data detailing the biophysical characteristics of different
ion channels, a number of viral gene therapy approaches to reduc-
ing pathological hyperexcitability have been explored. These range
from the knockdown or overexpression of ion channels that regu-
late neuroexcitability endogenously, to the delivery of exogenous
channels that permit manipulation of excitability via optical or
chemical means. In this review we discuss the different ion chan-
nel gene therapy approaches that show promise in the treatment
of chronic pain and/or epilepsy. We consider the translational hur-
dles facing each, as well as the difﬁculties associated with clinical
progression of gene therapy in general.
2. Optogenetics
The development of optogenetics over the past decade has rev-
olutionised many branches of basic neuroscience research [35].
The technique employs a set of microbial ion channels and pumps
that activate upon stimulation by particular wavelengths of light.
After transgenic expression within neurons, these type I opsins
permit optical modulation of membrane depolarisation or hyper-
polarisation with temporal precision on the order of milliseconds.
When combined with the spatial speciﬁcity created by placing
opsins under the control of cell type speciﬁc promoters, this gener-
ates a system capable of exquisite on-demand regulation of
excitability and ﬁring in a genetically deﬁned population of neu-
rons. In this section we review the therapeutic potential of optoge-
netics for the treatment of chronic pain and epilepsy.
2.1. Epilepsy
Epileptiform activity is believed to arise from an
excitation-inhibition imbalance within neuronal networks. This
balance can be restored by either downregulating excitation or
upregulating inhibition.
2.1.1. Upregulating inhibition
Upregulation of inhibition can be achieved by optical stimula-
tion of GABAergic inhibitory interneurons expressing
algae-derived channelrhodopsin-2 (ChR2). Activation of this
non-selective cation channel with 450–490 nm blue light produces
marked neuronal depolarisation and AP ﬁring [36,37].
ChR2-mediated stimulation of interneurons was recently
exploited for therapeutic effect in a rodent model of temporal lobe
epilepsy (TLE). Mice expressing ChR2 exclusively within
parvalbumin-positive (PV+) interneurons were generated by cross-
ing animals expressing Cre under the PV promoter with those car-
rying Cre-dependent ChR2. In the resulting PV-ChR2 offspring,in vivo optical stimulation of the hippocampal formation signiﬁ-
cantly attenuated established seizures induced by intrahippocam-
pal injection of kainic acid; almost 60% of seizures detected online
via automated electroencephalographic (EEG) analysis were
stopped within 5 s of ChR2 activation, and average seizure duration
fell by more than 40% [38]. Although opsin delivery via selective
breeding is obviously not feasible in a clinical setting, this study
provided proof-of-principle that optogenetic stimulation of
GABAergic interneurons could attenuate seizures in vivo.
Stimulation of just one genetically deﬁned neuronal population,
the perisomatic-targeting PV+ interneurons, was sufﬁcient to reli-
ably suppress seizures. This result has inevitably fuelled debate
over which interneuronal subtype should be stimulated for opti-
mal anti-seizure efﬁcacy. PV+ interneurons are known to play
important roles in subduing and synchronising the axonal output
of CA3 hippocampal pyramidal neurons [39], yet recent recordings
from CA1 have suggested dendritic-targeting somatostatin-
positive (SST+) interneurons may have an even stronger inﬂuence
on pyramidal cell AP generation [40]. Work from Ledri and col-
leagues supports an approach based on global activation of
interneurons. In acute hippocampal slices frommice transgenically
expressing ChR2, optical silencing of chemically-induced epilepti-
form activity was more effective when the opsin was expressed
throughout GABAergic interneurons than when it was expressed
speciﬁcally within PV+ or SST+ subpopulations [41].
2.1.2. Downregulating excitation
Downregulation of excitation can be achieved by optical stimu-
lation of excitatory glutamatergic neurons expressing
halobacteria-derived halorhodopsins (HRs). These chloride pumps
are preferentially activated by orange/yellow light with a wave-
length 590 nm. When transgenically expressed within neurons,
such activation elicits membrane hyperpolarisation capable of sup-
pressing the generation of APs [42].
The anti-epileptic potential of HR-mediated neuronal silencing
has been investigated by a number of groups. In early ex vivo work
by Tønnesen and colleagues, mouse pups received intrahippocam-
pal injections of a lentivirus encoding an HR under the control of
the glutamatergic neuron-speciﬁc calcium/calmodulin-dependent
protein kinase IIa (CaMKIIa) promoter. In hippocampal organ-
otypic slice cultures prepared from these animals, optical stimula-
tion signiﬁcantly attenuated epileptiform bursting induced by high
frequency stimulus trains or the GABAA receptor (GABAAR) blocker
picrotoxin [43].
These promising ex vivo ﬁndings set the stage for more recent
work demonstrating HR-mediated seizure suppression in vivo. In
a breeding strategy similar to that used to deliver ChR2 to PV+
interneurons, mice expressing HR exclusively within excitatory
principal neurons were generated by crossing animals expressing
Cre under the CaMKIIa promoter with those carrying
Cre-dependent HR. In the CaMKIIa-HR offspring, optical stimula-
tion of the hippocampal formation again successfully attenuated
established seizures elicited by intrahippocampal kainic acid.
Nearly 60% of seizures detected online were stopped within 1 s
of HR activation, and average seizure duration fell by 70% [38].
As for Cre-dependent delivery of ChR2 to interneurons, the
weakness of this approach from a translational perspective is its
reliance on selective breeding to express HR exclusively within
glutamatergic neurons. Should optogenetics progress to the clinic,
opsins will need to be delivered using viral vectors. In work by our
group, injection of an HR-encoding lentivirus into layer V of the rat
motor cortex produced preferential expression of the opsin within
excitatory principal neurons. Subsequent optical stimulation of
these neurons in a tetanus toxin model of chronic focal neocortical
epilepsy signiﬁcantly diminished established epileptiform activity
in the absence of behavioural side effects [44].
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was unexpected given that the transgene was placed under the
control of a non-cell type speciﬁc cytomegalovirus (CMV) pro-
moter. For translation to the clinic, a more sensible approach
would guarantee glutamatergic neuron-speciﬁc opsin expression
with the use of a CaMKIIa promoter. The therapeutic potential of
such a construct has recently been demonstrated in a rat model
of thalamocortical epilepsy [45]. CaMKIIa promoter-driven HR
was delivered to excitatory neurons of the ventrobasal thalamus
using a serotype-5 adeno-associated viral vector (AAV5). Optical
stimulation of transduced thalamocortical neurons reliably inter-
rupted cortical seizures established after photothrombotic induc-
tion of stroke.
Intracellular chloride accumulation is a frequent concern in the
ﬁeld of HR-based optogenetics. Chloride accumulation can shift the
reversal potential of GABAAR-mediated inhibitory postsynaptic
currents, causing them to become depolarising [46]. For the treat-
ment of chronic pain and epilepsy such a shift would be particu-
larly problematic, as optical stimulation would begin to
exacerbate rather than suppress neuronal hyperexcitability. This
is especially true for disorders in which chloride ion homeostasis
may already be adversely disrupted, such as TLE [47]. Although
not all HR variants elicit excessive intracellular chloride accumula-
tion [43], the issue can be avoided by modifying the optogenetic
strategy. The use of pulsed rather than continuous optical stimula-
tion, for example, would allow endogenous chloride extrusion
pumps (e.g. KCC2) more time to counteract chloride inﬂux [48].
Alternatively, HR might be exchanged for a hyperpolarising opsin
that pumps protons rather than chloride ions, such as Arch or
ArchT [49,50]. Such proton pumps have yet to be utilised for
in vivo seizure suppression.
2.2. Chronic pain
The transmission of nociceptive signals from the periphery to
the spinal cord is mediated by small-diameter dorsal root ganglion
(DRG) neurons. So named for the location of their somata, these
pseudounipolar neurons have a bifurcating axon that projects in
one direction to the periphery and in another to the dorsal horn
of the spinal cord. Hyperexcitability within nociceptive afferents
is a critical feature of many forms of inﬂammatory and neuropathic
chronic pain [32,51]. Consequently, optogenetic silencing of these
neurons represents a potentially efﬁcacious alternative to classical
analgesic intervention. Although optogenetic techniques have been
used to modulate the ﬁring of nociceptive neurons in vitro, the fea-
sibility of in vivo therapeutic silencing has long been doubted due
to the misconception that DRG neurons would need to be optically
stimulated along their entire length. As this can be more than a
metre in some adult humans, the technical difﬁculties of total illu-
mination are self-evident.
However, recent work in rodents suggests these concerns may
have been unfounded. Using an AAV6 vector encoding HR under
the neuron-speciﬁc synapsin promoter, Iyer and colleagues
expressed the inhibitory opsin within DRG neurons of the mouse
hindlimb. Although viral transduction was not speciﬁc for nocicep-
tive neurons, subsequent optical stimulation produced an acute
analgesic effect, and completely reversed the mechanical and ther-
mal hypersensitivity experienced in a chronic sciatic nerve con-
striction model of neuropathic pain [52]. An acute analgesic
effect has also been achieved with optogenetic inhibition of DRG
neurons expressing the light-sensitive proton pump ArchT [53].
In an attempt to selectively transduce nociceptive afferents, an
AAV5 vector was designed in which the ArchT transgene was
placed under the control of a transient receptor potential cation
channel subfamily V member 1 (TRPV1) promoter; TRPV1 is a
non-selective cation channel preferentially expressed withinnociceptive DRG neurons [54]. Optical stimulation of afferents
transduced by direct intraganglion injection of the AAV5 vector
resulted in signiﬁcant increases in the thresholds for acute thermal
and mechanical pain. A very promising aspect of these two studies
was that optical stimuli were delivered transdermally, by shining
light on the hindpaw corresponding to the injected/ligated nerve
or ganglion. Techniques such as this, which eliminate the need
for surgical implantation of stimulation devices, will obviously
have a tremendous impact on the speed with which optogenetic
therapy can progress to the clinic.
In the work described above analgesic effects were elicited via
optogenetic inhibition of neurons within the ascending nociceptive
neural pathway. Endogenously, pain perception is heavily modiﬁed
in both a pro- and anti-nociceptive manner by descending projec-
tions emanating from various regions of the brainstem [55–57].
Recent work by Hickey et al. investigated whether optogenetic
stimulation of one such region, the locus coeruleus (LC), could
attenuate peripheral nociception [58]. A lentiviral vector encoding
ChR2 under the control of a catecholaminergic-speciﬁc PRS pro-
moter was used to target expression of the opsin transgene to pon-
tospinal noradrenergic neurons of the LC. In lightly anaesthetised
rats, optical stimulation of these neurons in the ventral, but not
dorsal, portion of the LC signiﬁcantly increased withdrawal thresh-
olds to a thermal nociceptive stimulus applied to hindpaw.
Although this study did not investigate analgesic efﬁcacy in a
model of chronic pain, and experiments were performed on anaes-
thetised rather than freely behaving animals, it nevertheless repre-
sents an exciting proof-of-concept for modulating pain perception
via optogenetic stimulation of central brain regions. In the future
this may prove therapeutically useful in more global chronic pain
conditions that are not amenable to treatment by local suppression
of DRG neuron excitability.
2.3. Translating optogenetics to the clinic
The future for optogenetic therapy of disorders of neuronal
hyperexcitability looks bright. Despite encouraging experimental
advances however, several translational hurdles must still be
overcome.
The ﬁrst of these is a technical issue concerning the miniaturi-
sation of stimulation devices. The power expenditures required
for optical neuromodulation are vast; stimulation of an equivalent
volume of brain tissue by more archaic electrical means can use as
little as one-thousandth of the energy [59]. Creating a fully inte-
grated, implantable device that can generate continuous optical
signals for a therapeutically useful length of time will therefore
require considerable battery power, and as battery power
increases, so must device size. These devices need not be
implanted at the site of stimulation; subcutaneous placement will
sufﬁce if narrow ﬁbre optic cables are used to transmit light signals
to opsin-expressing neurons. But this does not eliminate the need
for miniaturisation. Indeed the size of implanted equipment is
likely to be an important factor determining acceptance of optoge-
netic techniques into the clinic, by patients and clinicians alike.
The miniaturisation of optical stimulation devices will be driven
predominantly by technical advances in the ﬁelds of bioengineer-
ing and power storage [60]. The molecular engineering of opsins
will also contribute. One such innovative approach exploits single
amino acid substitutions to alter opsin deactivation kinetics. The
resulting molecules, termed step-function opsins (SFOs), display
prolonged open states that long outlast the activating stimulus
[61,62]. From a translational perspective these SFOs represent an
impressive energy-saving tool, capable of dramatically reducing
stimulation device size by permitting long-term (tens of minutes)
modulation of neuronal excitability with short-term (tens of mil-
liseconds) optical illumination.
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devices used clinically will be the ability to simultaneously detect
and suppress seizures. Such ‘‘closed-loop’’ systems have already
been trialled in vivo with notable success [38,45,63]. However,
their clinical translation will be hampered by a number of issues.
First amongst these is the selection of an appropriate seizure
detection algorithm. Deconstructing EEG traces to reliably and
automatically detect epileptiform activity still represents a central
challenge in epilepsy research [64,65], and was recently the subject
of a contest jointly sponsored by NINDS, the American Epilepsy
Society and the Epilepsy Foundation (http://ieeg.org). In a
closed-loop system, compromises between the speed and accuracy
of seizure detection will inevitably have to be made, and selecting
a suitable approach for the clinic can only be guided by extensive
in vivo testing. One exciting prospect is the emergence of seizure
prediction algorithms for pre-emptive ictal silencing. Although
these have classically suffered from poor reliability, promising
recent advances have been made [66].
Unfortunately the creation of closed-loop systems will only
exacerbate the issue of device miniaturisation. Current approaches
employ tethered set-ups that connect EEG electrodes to external
ampliﬁers and computers. Such tethering is obviously not feasible
in a clinical setting, and signiﬁcant technological advances will be
necessary if seizure detection and suppression capabilities are to
be combined into a fully integrated, implantable system.
Perhaps the greatest hurdle facing clinical translation of
optogenetics is the poor penetration of visible light through brain
tissue due to photon scattering and absorption [67]. Gradinaru
and colleagues, for example, report that light power sufﬁcient to
activate an enhanced HR is only present up to 1.5 mm from the
tip of an optical ﬁbre with a 30 mW output [68]. Although such
shallow penetration might sufﬁce in rodent disease models,
producing therapeutic efﬁcacy in humans with brains many times
larger will require optical stimulation of much greater tissue
volumes [48].
Increasing the strength and/or number of optical stimuli seems
like the most straightforward solution to this problem. However,
the requisite increases in device size are undesirable, and local
heating effects from sustained stimulation with powers in excess
of 100 mW/mm2 can lead to irreversible tissue damage [69]. An
increase in tissue damage is also likely to accompany the implan-
tation of multiple optic ﬁbres, particularly if they are targeted to
deep brain regions. Moreover, there is a risk that optical stimula-
tion will be compromised if ﬁbre tips are encased by connective
tissue or shifted out of position after surgery [59]; the probability
of such outcomes evidently increases with an increasing number of
ﬁbres.
To overcome the issue of poor light penetration the molecular
engineering of opsins may again prove critical. By rendering opsins
more sensitive to optical activation at their preferred wavelengths,
weaker signals further from a stimulating source are able to mod-
ulate neuronal excitability [70]. A more innovative approach
increases the sensitivity of opsins to longer wavelengths of light,
creating so-called red-shifted opsins (RSOs) [71,72]. As light of
longer wavelength has greater tissue penetration [73], RSOs also
permit modulation of excitability in neurons much further from
an optical source, opening optogenetic stimulation up to deep
and diffuse brain structures for which implantation of optical ﬁbres
may be deemed too invasive. In addition, RSOs also offer the tanta-
lising prospect of non-invasive transcranial optogenetics; as dis-
cussed above, proof-of-principle for transdermal optogenetic
modulation of DRG neuron ﬁring has already been demonstrated
[52,53,74]. And ﬁnally, RSOs could permit bimodal suppression of
neuronal excitability. Expressing within inhibitory neurons a
red-shifted ChR2 with a wavelength preference matching that of
an excitatory neuron-expressed HR would allow coincidentexcitatory inhibition and inhibitory excitation by a
single-wavelength optical stimulus [69]. It remains to be seen
whether such an approach could be optimised to generate thera-
peutic efﬁcacy superior to the single-opsin convention.
The many technical challenges associated with in vivo optoge-
netic modulation of neuroexcitability means successful clinical
translation is still several years away. However, the essential role
optogenetics now plays in many branches of basic neuroscience
research will continue to drive rapid advances in the technology
of stimulation devices [60] and the molecular engineering of opsins
[72,75], both of which will have considerable translational impact.
3. Chemogenetics
The ability to modulate neuronal excitability via on-demand
activation of ion channels is not an exclusive property of optoge-
netics. Chemogenetic techniques achieve a similar feat using trans-
genic expression of channels gated by ligands. As administration of
these ligands in vivo is typically performed systemically, the
chemogenetic approach avoids the complications of optogenetics
arising from the need for local light delivery. Invasive surgery apart
from injection of the viral vector is not necessary, and deep and dif-
fuse neural structures can be targeted.
It should be noted that chemogenetic tools are not restricted to
ion channels; a number of G protein-coupled receptors (GPCRs)
have been developed that modulate neuronal excitability indi-
rectly via activation of intracellular second messenger cascades
[76–78]. Although these GPCRs have recently demonstrated
impressive anti-seizure efﬁcacy [79], they fall beyond the scope
of this review.
3.1. Chloride channels
Ligand-gated chloride channels permit chemogenetic suppres-
sion of neuronal excitability. The glutamate-gated chloride channel
from Caenorhabditis elegans, GluCl, has proven particularly popular.
A heteropentamer composed of a and b subunits, GluCl is activated
by ivermectin (IVM), a widely used and orally available
anti-parasite drug [80]. Since the early demonstration of its ability
to silence neurons [81], GluCl has been optimised for use in mam-
malian cells [82,83]. One important modiﬁcation has been the
introduction of a single amino acid substitution that dramatically
reduces the channel’s sensitivity to glutamate [83]. By ensuring
GluCl can only be activated by exogenously delivered IVM, this
mutation confers upon the channel the property of orthogonality.
Orthogonality, the lack of endogenous interaction partners for
either the receptor or its cognate ligand, is essential for limiting
off-target effects during chemogenetic (and optogenetic)
stimulation.
Transgenic expression of GluCl allows regulation of neuronal
excitability in vivo in an IVM-dependent manner. In the ﬁrst exam-
ple of behavioural modiﬁcation using ion channel chemogenetics,
mice received unilateral striatal injections of AAV2 vectors encod-
ing a and b GluCl subunits. When IVM was systemically adminis-
tered via intraperitoneal injection, the resulting suppression of
dopaminergic neurotransmission initiated amphetamine-induced
rotational behaviour. This effect emerged within 4 h of IVM deliv-
ery and was completely reversed 4 days later [84].
Although behavioural modiﬁcation using GluCl/IVM has been
achieved by numerous groups since [85–87], the therapeutic
potential of the system for treatment of chronic pain and epilepsy
has yet to be evaluated. In addition to its protracted on/off kinetics,
the GluCl/IVM system is limited by the high doses of IVM required
to achieve consistent neuronal silencing [88]. As IVM is known to
activate a range of endogenous central nervous system (CNS)
receptors at high concentrations [89–92], this dosing limitation
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concerns have recently been assuaged by the design of modiﬁed
GluCl channels with greater sensitivity to IVM [93].
One ‘‘chemogenetic’’ chloride channel that has demonstrated
therapeutic potential is the human glycine receptor (hGlyR).
Although endogenous expression of hGlyRs within the CNS pre-
cludes any intervention targeted to the brain or spinal cord, the
receptor is absent from primary sensory neurons, suggesting it
could be used to suppress DRG neuroexcitability for the treatment
of chronic pain. Employing just such an approach, Goss and col-
leagues delivered the hGlyRa1 subunit to sensory afferents of the
rat hindlimb using subcutaneous hindpaw injections of a herpes
simplex virus (HSV) vector [94]. Although viral transduction was
not speciﬁc for nociceptive DRG neurons, subsequent local applica-
tion of glycine generated profound analgesia in two separate mod-
els of inﬂammatory chronic pain. The system also demonstrated
therapeutic efﬁcacy in a model of visceral inﬂammatory pain.
After injection of the hGlyRa1-encoding HSV vector directly into
the bladder wall, intravenous glycine administration reversed
chemically induced bladder hypercontractility.
3.2. The capsaicin receptor
As demonstrated by the ChR2-based optogenetic strategies
described above, chemogenetic enhancement of excitability within
the CNS may prove therapeutically beneﬁcial in the treatment of
chronic pain and epilepsy. For neuronal activation, the
best-characterised chemogenetic ion channel is the TRPV1 recep-
tor. As mentioned above, TRPV1 is a non-selective cation channel
expressed predominantly within nociceptive DRG neurons. An
essential nociceptor, the channel is gated by heat, protons and cap-
saicin, an active component of chilli peppers that serves as the cog-
nate ligand in chemogenetic applications [54].
Although the TRPV1/capsaicin system has been used to success-
fully enhance neuronal activity both in vitro [95] and in vivo [96],
it is unsuitable for clinical use for a number of reasons [88]. First,
orthogonality is compromised by endogenous TRPV1 expression
within the mammalian brain [97], and activation of these receptors
by endocannabinoid neuromodulators [98]. Second, transgenic
TRPV1 expression has been shown to alter aspects of intrinsic neu-
ronal excitability (e.g. resting membrane potential) in the absence
of capsaicin activation [95]. Third, the calcium permeability of
TRPV1 receptors means high doses of capsaicin can lead to neu-
ronal excitotoxicity [96]. And fourth, administration of capsaicin
to central regions could only be performed by intracranial infusion,
as systemic delivery would activate peripheral TRPV1 receptors
causing intense pain.
Thus, while the TRPV1/capsaicin system may continue to play
an important role in chemogenetic neuronal activation in a
research setting [99], the approach does not at present display
therapeutic potential for the treatment of chronic pain or epilepsy.
3.3. Engineered channels and ligands
Engineered ligand-gated ion channels (eLGICs) represent an
exciting technical advance in the ﬁeld of ion channel chemogenet-
ics. The ligand-binding domain (LBD) of the a7 nicotinic acetyl-
choline receptor (nAChR) behaves as an independent actuator
module in the cys-loop family of ionotropic receptors [100]. This
means it can be combined with the ion pore domain (IPD) of any
cys-loop receptor to create a chimeric channel gated by ACh. In
recent work by Magnus and colleagues, a7 LBDs were mutated
to yield pharmacologically selective actuator molecules (PSAMs)
that are unresponsive to ACh but selectively gated by synthetic
ligands termed pharmacologically selective effector molecules
(PSEMs) [101]. These PSAM domains were combined with distinctcys-loop receptor IPDs permeable to calcium ions, cations or chlo-
ride ions, creating a toolkit of orthogonal ligand-gated channels
with the ability to depolarise or hyperpolarise neurons in which
they were expressed. Since their creation, these eLGICs have been
used by a number of groups in vivo to chemogenetically modify
rodent behaviour [102–105]. As expected given their bespoke
design, the PSAM/PSEM systems display unfailing orthogonality,
and relatively rapid on/off kinetics have been reported (effect onset
and brain clearance within one hour of systemic PSEM administra-
tion) [101].
Despite such encouraging early results, the therapeutic poten-
tial of these engineered channels for the treatment of chronic pain
and epilepsy has yet to be explored. Nevertheless, they will clearly
form the foundation of rapid advances in the development of ion
channel chemogenetics for both basic neuroscience research and
clinical intervention. The cys-loop family of ligand-gated channels
comprises no less than 43 vertebrate subunits [106], all with
diverse ion selectivity and conductance properties. This is a vast
library fromwhich any IPD could theoretically be selected to create
an orthogonal channel with properties ideally suited to a
researcher or patient’s particular needs.
3.4. Translating chemogenetics to the clinic
While direct evidence for the therapeutic potential of ion chan-
nel chemogenetics in the treatment of chronic pain and epilepsy is
still lacking, the approach is clinically attractive. Like optogenetics,
chemogenetics permits on-demand, graded modulation of neu-
ronal excitability in a genetically deﬁned population of cells.
Unlike its optical cousin however, chemogenetics does not rely
on local delivery of an activating stimulus; ligands can be adminis-
tered systemically (often orally), allowing deep and diffuse neural
structures to be targeted without invasive implantation of any
stimulation device.
One important weakness of the chemogenetic approach is its
temporal imprecision [107]. In stark contrast to the millisecond
precision of optogenetics, chemogenetic modulation of neuronal
excitability can display onset latencies of tens of minutes to hours
depending on the system used, and there is often a signiﬁcant
delay between the termination of ligand delivery and the return
of excitability to baseline. For the treatment of chronic pain or epi-
lepsy characterised by persistent seizures, such temporal impreci-
sion could be acceptable, but this is unlikely to be the case for
epileptic conditions in which seizures present sporadically, and
patients do not have sufﬁcient warning to pre-emptively adminis-
ter an activating ligand. Ictal episodes that are preceded by pre-
monitory auras or cluster at predictable times (e.g., in catamenial
epilepsy) might be more amenable to chemogenetic intervention
[79].
One way that onset latencies might be reduced is through the
use of subcutaneous pumps that deliver activating ligands intra-
venously. Although these would require surgical implantation,
they would completely abolish temporal delays arising from oro-
gastric absorption of orally delivered agonists. Pumps could also
potentially be incorporated into closed-loop devices that dispense
ligands automatically upon detection of pathological hyperex-
citability [79].
4. Overexpression or knockdown of endogenous ion channels
The greatest hurdles facing clinical translation of optogenetic
and chemogenetic techniques stem from their need to deliver
exogenous agents, light or ligands, to modulate neuronal excitabil-
ity. These hurdles can be avoided by employing a gene therapy
strategy that constitutively modiﬁes the expression of endogenous
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removes the capacity to attenuate seizures or pain on-demand, this
approach is attractive for its relative simplicity and the variety of
potential targets.
4.1. Modulating intrinsic neuronal excitability
Modulating intrinsic excitability represents the most direct
route by which neuronal ﬁring can be manipulated for therapeutic
means. Altering the expression of sodium and potassium channels
allows modiﬁcation of intrinsic excitability without any effect on
calcium-dependent signalling.
4.1.1. Overexpressing potassium channels
As essential suppressors of intrinsic excitability, potassium
channels can be overexpressed to therapeutically subdue the activ-
ity of neurons, or to silence them entirely.
For analgesic purposes, research along this avenue has focussed
on the inwardly rectifying potassium channel 2.1 (Kir2.1). Kir2.1
overexpression has been shown to dampen excitability in several
neuronal subtypes both in vitro [108,109] and in vivo [110].
Adenoviral delivery of the Kir2.1 gene to rat DRG neurons signiﬁ-
cantly reduced the hyperexcitability emerging from chronic gan-
glion compression [111]. When the viral vector was administered
immediately after the compression insult, the development of
mechanical hyperalgesia in this model of neuropathic pain was
partially prevented. This ﬁnding suggests Kir2.1 overexpression
could be used clinically in a preventative context, to minimise
the risk of developing chronic pain after peripheral nerve injury.
Delayed induction of Kir2.1 overexpression did not signiﬁcantly
inﬂuence pain behaviour, suggesting the approach cannot provide
analgesic relief after a chronic pain state has already been estab-
lished. This lack of effect may be the result of irreversible central
sensitisation processes that maintain upregulated nociceptive sig-
nalling irrespective of subsequent changes in primary afferent
ﬁring.
For the suppression of neuronal hyperexcitability in epilepsy,
two types of potassium channel have been tested in vivo. In work
by our group, established neocortical seizures in a tetanus toxin rat
model of chronic refractory epilepsy were progressively sup-
pressed by lentiviral delivery of a human voltage-gated potassium
channel subfamily A member 1 (KV1.1) gene [44]. A more recent
study has demonstrated the anticonvulsant efﬁcacy of transgenic
introduction of a 2-pore domain potassium leak channel.
Intrahippocampal injection of an AAV5 vector encoding a constitu-
tively active TWIK-related potassium (TREK) channel led to a sig-
niﬁcant reduction in the duration of acute seizures elicited by
lithium pilocarpine [112]. In both these studies, transgene expres-
sion was observed predominantly within excitatory neurons
despite the use of non-cell type speciﬁc promoters. As with any
gene therapy approach, it is essential that potassium channels
are overexpressed in the correct neuronal subtypes; high levels
of expression within GABAergic interneurons for example could
amplify pathological hyperexcitability.4.1.2. Knocking down voltage-gated sodium channels
Voltage-gated sodium channels (Navs) are important enhancers
of intrinsic excitability, making Nav knockdown an attractive
approach in the therapeutic attenuation of neuronal activity.
Chronic pain seems particularly amenable to gene therapy
approaches based on Nav knockdown; Nav upregulation con-
tributes heavily to the increases in DRG neuron excitability seen
in neuropathic [113,114] and inﬂammatory [115,116] pain disor-
ders, and many clinically prescribed analgesic drugs function by
Nav antagonism [117].To avoid unwanted side effects arising from global Nav knock-
down within somatosensory afferents, therapeutic strategies have
focussed on Nav isoforms expressed predominantly within noci-
ceptive neurons. Nav1.7, encoded by SCN9A, is one such isoform.
Abundantly and preferentially expressed within nociceptive DRG
neurons [118], Nav1.7 mutations are associated with a range of
genetic pain disorders [119,120]. In 2005 Yeomans and colleagues
investigated the therapeutic potential of DRG Nav1.7 knockdown
for the treatment of inﬂammatory chronic pain [121]. Transgenic
expression of an HSV vector-delivered SCN9A antisense sequence
completely prevented the emergence of thermal hyperalgesia after
hindpaw injection of the immunopotentiator complete Freund’s
adjuvant (CFA). Nav1.7 knockdown in DRG neurons has also proven
therapeutically efﬁcacious in a rat model of painful diabetic neu-
ropathy (PDN). HSV vector delivery of a Nav-targeting microRNA
completely reversed the increases in DRG Nav1.7 expression that
followed induction of diabetes with streptozotocin, and in doing
so signiﬁcantly reduced PDN-associated cold allodynia and ther-
mal and mechanical hyperalgesia [122].
Nav1.7 is not the only isoform whose knockdown may provide
long-lasting protection from chronic pain; Nav1.3, encoded by
SCN3A, is another promising candidate. Although normally
expressed at very low levels in adult neurons [123], Nav1.3 expres-
sion is dramatically upregulated following nerve injury [124],
when the isoform is thought to play an important role in the emer-
gence of neuronal hyperexcitability [125]. In recent work from the
group of Stephen Waxman, two Nav1.3-targeted short hairpin
RNAs (shRNAs) were packaged into separate AAV2 vectors injected
directly into the DRG of rats with partial ligation of the sciatic
nerve. The resulting Nav1.3 knockdown led to partial attenuation
of mechanical allodynia in this model of neuropathic pain; both
shRNAs were equally efﬁcacious [126].
These studies demonstrate the therapeutic potential of
isoform-speciﬁc DRG Nav knockdown for the treatment of inﬂam-
matory and neuropathic chronic pain. Although sodium channels
are strongly implicated in epileptogenesis, and several front line
anti-epileptic drugs selectively inhibit these channels [127,128],
Nav knockdown has yet to be investigated for its therapeutic effect
in models of epilepsy. This may be due to difﬁculties in selecting an
appropriate Na v target, or concerns about potential off-target
effects on physiological network activity.4.2. Modulating synaptic excitability
Modulating intrinsic excitability is not the only way by which
neuronal ﬁring can be manipulated. Within neuronal networks,
activity can also be modiﬁed by varying the degree of excitatory
or inhibitory synaptic input. One way to achieve this is via up- or
down-regulating the expression of excitatory or inhibitory neuro-
transmitter receptors. From a gene therapy perspective, the most
popular targets in this regard have been NMDA and GABAA
receptors.
4.2.1. Knocking down NMDA receptors
NMDA receptors (NMDARs) play a critical role in excitatory glu-
tamatergic synaptic transmission within the CNS. Receptor activa-
tion results in a non-selective cation ﬂux that underlies the slow
component of the fast excitatory post-synaptic current [129].
Increases in post-synaptic calcium following NMDAR activation
are known to be crucial for activity-dependent strengthening of
synaptic transmission [130], and this synaptic plasticity is often
essential for long-term enhancement of network excitability.
Perhaps unsurprisingly therefore, a number of studies have
explored the therapeutic potential of NMDAR knockdown for the
treatment of disorders of neuronal hyperexcitability.
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investigating whether functional NMDAR knockdown could be
achieved by eliciting a humoral immune response against the
receptor’s obligatory NR1 subunit [131]. Transduction of intestinal
M cells using a perorally administered NR1-encoding AAV was
used to generate this response. Surprisingly, the resulting
anti-NR1 antibodies seemed to protect sensitised animals against
seizures induced by systemic kainic acid. Moreover, the relative
impermeability of the non-seizure-compromised blood–brain bar-
rier (BBB) to the antibodies ensured NMDAR blockade was minimal
under resting physiological conditions. Despite these encouraging
experimental outcomes, this approach is probably unfeasible from
a translational perspective. The risk of side effects arising from glo-
bal NR1 knockdown is signiﬁcant, and anti-NR1 antibodies are now
thought to be pathogenic in their own right [132].
The therapeutic potential of NMDAR knockdown using more
direct gene-silencing constructs has also been investigated.
AAV-mediated delivery of a CMV-driven NR1 antisense sequence
was shown to signiﬁcantly increase thresholds for the electrical
induction of focal seizures in the rat temporal cortex [133].
Similar anticonvulsant efﬁcacy has been achieved with
shRNA-mediated NR1 knockdown. Intrahippocampal injection of
an AAV1/2 chimera encoding an NR1-targeted shRNA under the
control of the non-cell type speciﬁc U6 promoter protected rats
against seizures induced by local kainic acid administration
[134]. However, such protection came at the expense of impaired
hippocampal-dependent learning and compromised neurogenesis.
Whether these adverse effects will render central NMDAR knock-
down clinically untenable remains to be seen.
NMDAR knockdown outside the brain may display a more for-
giving side effect proﬁle, and several studies have investigated this
approach for its analgesic potential [135–138]. The ﬁrst synapse in
the ascending nociceptive neural pathway, between DRG primary
afferents and neurons of the spinal cord dorsal horn, has proven
a particularly popular target; NMDAR-dependent strengthening
at this synapse can underlie certain forms of central sensitisation
[139]. In work by Garraway and colleagues, an AAV vector encod-
ing an NR1-targeted shRNA was delivered directly to the dorsal
horn of mice by intraparenchymal injection. The resulting NR1
knockdown had no effect on the perception of acute nociceptive
stimuli, but did prevent the emergence of mechanical allodynia
after CFA-mediated induction of inﬂammatory chronic pain
[140]. Similar ﬁndings were obtained in rats with chronic pain
induced by the inﬂammatory agent formalin [141]. These studies
suggest that inhibiting central sensitisation by knocking down
NMDARs at the DRG neuron-dorsal horn synapse may prove ther-
apeutically efﬁcacious in preventing the emergence of chronic pain
after peripheral tissue damage.
4.2.2. Overexpressing GABAA receptors
GABAARs play an essential role in inhibitory synaptic transmis-
sion within the CNS. Overexpressing this chloride-permeable iono-
tropic receptor thus has the potential to therapeutically suppress
local network excitability. Within the dentate gyri of pilocarpine
rat models of TLE, there are signiﬁcant reductions in the expression
of GABAAR a1 subunits accompanied by signiﬁcant increases in
levels of a4 [142,143]. In an innovative attempt to reverse this
a1 deﬁcit, Raol and colleagues designed an AAV2 vector that
encoded the a1 gene (GABRA1) under the control of the a4 gene
(GABRA4) promoter. When this vector was injected directly into
epileptic dentate gyri, the enhanced a1 expression not only atten-
uated acute pilocarpine-induced seizures, but also decreased by
60% the number of rats that went on to develop established epi-
lepsy [144]. It should be noted that a signiﬁcant proportion of
AAV2-a1-treated rats experienced behavioural abnormalities such
as excessive sedation and weight loss. This suggests that, as withNMDAR knockdown, the clinical translation of GABAAR overex-
pression may be hindered by adverse side effects.
4.2.3. Knocking down TRPV1 receptors
Although the knockdown of TRPV1 receptors within DRG neu-
rons strictly represents a modiﬁcation of neither intrinsic nor
synaptic excitability, the approach has recently been used for mild
analgesic effect in a mouse model of neuropathic pain [145]. A
TRPV1-targeting shRNA was packaged into an AAV9 vector and
administered via intrathecal injection to mice with partial ligation
of the sciatic nerve. TRPV1 knockdown resulted in a slight but sig-
niﬁcant increase in the hindpaw withdrawal threshold to a 50 C
thermal stimulus. However, the fact that no signiﬁcant changes
were observed in withdrawal thresholds for a thermal stimulus
5 C hotter, an acetone-induced noxious cold stimulus, or a focal
mechanical stimulus suggests this approach may struggle in its
clinical translation.
4.3. Translating overexpression or knockdown of endogenous ion
channels to the clinic
Gene therapy approaches based on overexpression or knock-
down of endogenous ion channels will likely progress to the clinic
much more rapidly than optogenetic or chemogenetic methods.
Technical hurdles stemming from the need to deliver activating
light or chemical stimuli do not exist, and the burden of
pre-clinical safety and tolerability testing will probably be signiﬁ-
cantly lighter for human genes than those derived from distant
species [146].
Nevertheless these approaches still face a number of transla-
tional hurdles. Of particular concern is the constitutive nature of
the therapy, which could prove problematic for several reasons.
First, constitutive manipulation of neuronal excitability is more
likely to be counteracted by homeostatic compensatory mecha-
nisms than a therapeutic intervention delivered transiently and
intermittently [147]. Such compensation could adversely inﬂuence
excitability in other parts of the network, or simply abolish the
beneﬁcial effects of transgene expression, generating the need for
repeat vector administrations that become progressively less efﬁ-
cacious. The latter concern might be assuaged by the delivery of
transgenes speciﬁcally designed to resist compensatory downregu-
lation [112].
Second, constitutive manipulations will suppress neuronal
excitability continuously, whether pathological activity is present
or not. The aim of these interventions is to abolish
disease-related hyperexcitability, but the silencing of physiologi-
cally salient neuronal communication could generate unwanted
treatment side effects. This is less of a concern for chronic pain
or epilepsies characterised by persistent seizures, such as epilepsia
partialis continua, where ongoing suppression of excitability is
therapeutically necessary [148]. In the vast majority of epileptic
conditions however this is not the case, and seizures present spo-
radically separated by long periods of interictal activity.
Unfortunately the effects of ion channel gene therapy on interictal
activity are often ignored, and appropriately titrating a given treat-
ment to minimise the silencing of normal neuronal function can be
challenging.
Finally, should constitutive modulation of neuronal excitability
produce unwanted side effects, the intervention cannot simply be
‘‘switched off’’, as is achieved in optogenetics and chemogenetics
by removal of the activating stimulus. Such irreversibility in the
face of adverse treatment outcomes will necessitate careful subject
selection in the early phases of human testing. For epilepsy,
patients with seizure foci deemed suitable for surgical resection
would be ideal, as transduced tissue could be immediately excised
if undesirable side effects were to arise [44,146].
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efﬁcacious gene therapy
The studies presented above highlight the great variety of trans-
genes used to manipulate ion channel expression in the therapeu-
tic attenuation of neuronal hyperexcitability (summarised in Fig. 1
and Table 1). Selecting an appropriate transgene though is only the
ﬁrst step in producing a clinically viable gene therapy. To ensure
expression is achieved in the desired target neurons at levels sufﬁ-
cient to counteract pathological ﬁring, all in the absence of adverse
side effects, the promoter and viral vector employed for transgene





































Fig. 1. Schematic of the different gene therapy approaches used to alter neuronal
excitability via the manipulation of ion channel expression. The activity of a
hypothetical neuron is represented on the right as vertical spikes along a baseline.
Optogenetic channels permit light-mediated enhancement (ChR2) or suppression
(HR, ArchT) of neuronal ﬁring with a stimulus duration on the order of ms/s.
Chemogenetic channels also permit bidirectional modulation of spiking. Neuronal
ﬁring is dampened by chloride ion inﬂux through GluCl, hGlyR, and eLGICs-
channels, and increased by cation ﬂow through TRPV1 and eLGICs+ channels. In
both cases the channels are activated by pharmacological stimuli with effect
durations on the order of minutes to days. The expression of endogenous ion
channels can be manipulated to suppress neuronal excitability by increasing
potassium ion efﬂux (Kir2.1, Kv1.1, TREK), reducing cation inﬂux (Nav, NMDAR,
TRPV1), or increasing chloride inﬂux (GABAAR). In all cases the effects are long
lasting and most will likely be considered permanent in a clinical setting. As
indicated by the small number of remaining spikes, these approaches would ideally
spare a small amount of neuronal activity.different promoters and vectors that have been used in studies of
gene therapy for chronic pain and epilepsy. We then discuss the
regulatory, manufacturing and socioeconomic hurdles facing clini-
cal translation of gene therapy in general. A comprehensive discus-
sion of vector design, testing and approval is beyond the scope of
this article; more detailed accounts can be found in several excel-
lent recent reviews [15,146,149–152].
5.1. Viral vectors
Viral vectors vary considerably in their suitability for different
therapeutic applications. In studies investigating ion channel gene
therapy for chronic pain and epilepsy, four have so far been used:
lentiviral, AAV, HSV and, to a lesser extent, adenoviral vectors.5.1.1. Adenoviral vectors
Adenoviral vectors have proven a popular delivery strategy in
several gene therapy applications, particularly those targeting can-
cer and liver disease. The vectors have a transgene packaging
capacity of 8 kb (can be increased to >35 kb in so-called ‘‘gutless’’
vectors), and can efﬁciently transduce post-mitotic neurons to sup-
port high levels of transgene expression. Despite this, adenoviruses
are rarely selected for transgene delivery in the treatment of neu-
rological disorders [149]; indeed just one of the studies presented
above employs an adenoviral vector [111].
The most likely reasons for this are the vectors’ tendency to
support only short-term transgene expression and their signiﬁcant
immunogenic potential. The seriousness of this immunogenicity
was made clear in an early clinical trial of enzyme replacement
therapy for the non-fatal disease ornithine transcarbamylase
(OTC) deﬁciency. 18-year-old Jesse Gelsinger suffered an acute
immunoinﬂammatory response after intravenous delivery of an
OTC-encoding adenoviral vector, and died frommultiple organ fail-
ure 4 days later [12]. Although adenoviral vectors can be engi-
neered to reduce their immunogenic potential [153], and the
risks of an acute systemic response are greatly diminished by
delivery directly into the immune-privileged CNS, this early trial
continues to bias vector selection for neurological gene therapy
against adenoviruses.5.1.2. AAV vectors
AAVs are the most common vector in clinical trials of gene ther-
apy for neurological disease [149]. Their popularity is reﬂected in
the large number of studies that have employed AAV-mediated
transgene delivery in preclinical testing of gene therapy for chronic
pain and epilepsy [45,52,53,112,126,131,133,134,140,141,144,145].
Like adenoviral vectors AAVs are capable of transducing
post-mitotic neurons, but can support transgene expression of
much longer duration (up to 8 years in non-human primates
(NHPs) [154]). Moreover, AAVs are not associated with any human
diseases and although they can elicit both humoural and
cell-mediated immune responses, these tend to result simply in
vector elimination rather than acute systemic reactions [155].
AAV vectors do have limitations however. First amongst these is
their relatively small transgene packaging capacity (4.5 kb),
which may preclude delivery of therapeutic constructs containing
large promoter elements and/or ion channel genes. Another disad-
vantage is their occasional propensity for genomic integration.
Although the vast majority (99%) of AAV-delivered DNA persists
in extrachromosomal episomes, a small proportion of vectors inte-
grate their DNA into the genome of the host cell [156,157]. Such
integration is concerning as it can lead to a phenomenon known
as insertional mutagenesis, where potentially catastrophic muta-
tions arise from genomic insertions within or near the coding
regions of actively transcribed genes. While the large proportion
Table 1
Summary of the different ion channels investigated for gene therapy of chronic pain and epilepsy. For endogenous channels, arrows refer to the direction of the manipulation (" or
; for up- or down-regulation of expression, respectively). K and V represent the predicted effect of a given manipulation on neuronal ﬁring (enhancement or suppression,
respectively). Y (yes) and N (no) denote whether a given channel has been (Tested?) or could be (Feasible?) effectively utilised in gene therapy for epilepsy and/or pain.
Theoretically promising manipulations that have not yet been tested are given in bold. *denotes adverse side effects that may limit the therapeutic potential of central NMDAR





Analgesic potential Key references
Feasible? Tested? Feasible? Tested?
Optogenetic
channels
ChR2 K Y Y Y Y Krook-Magnuson et al. [38] Ledri et al. [41] Hickey et al. [58]
HR V Y Y Y Y Tønnesen et al. [43] Krook-Magnuson et al. [38] Wykes et al. [44] Paz
et al. [45] Iyer et al. [52]
ArchT V Y N Y Y Li et al. [53]
Chemogenetic
channels
GluCl V Y N Y N n/a
hGlyR V N N Y Y Goss et al. [94]
eLGICs- V Y N Y N n/a
TRPV1 K N N N N n/a
eLGICs+ K Y N Y N n/a
Endogenous
channels
Kir2.1 (") V Y N Y Y Ma et al. [111]
Kv1.1 (") V Y Y Y N Wykes et al. [44]
TREK (") V Y Y Y N Dey et al. [112]
Nav (;) V Y N Y Y Yeomans et al. [121] Chattopadhyay et al. [122] Samad et al. [126]
NMDAR
(;)
V Y⁄ Y Y Y During et al. [131] Haberman et al. [133] Kalev-Zylinska et al. [134]
Garraway et al. [140] Garraway et al. [141]
GABAAR
(")
V Y⁄ Y Y N Raol et al. [144]
TRPV1
(;)
V N N Y Y Hirai et al. [145]
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genesis unlikely, the consequences of ignoring the possibility can
be disastrous. In a 2002 gene therapy trial, retroviral delivery of
a cc chain transgene to patient-derived CD34+ bone marrow cells
was initially successful in treating X-linked severe combined
immunodeﬁciency (X-SCID) [158]. A subset of patients soon devel-
oped a leukemia-like condition however, the cause of which was
traced to transcriptional disruption arising from transgenic inte-
gration near the LMO-2 proto-oncogene [13]. No such adverse out-
comes have arisen from human gene therapy trials employing AAV
vectors, but oncogenic insertional mutagenesis after
AAV-mediated transgene delivery has been observed in rodents
[159].
AAVs comprise 12 identiﬁed human and NHP serotypes, and
over 100 isolated variants with unestablished serology [160].
Such variety, which stems from structural differences in the pro-
tein shell (capsid) of the virus, has provided a range of vectors with
diverse properties suiting different gene therapy applications. One
property that varies considerably among AAV serotypes is viral
tropism – the speciﬁc cells or tissues a virus will preferentially,
or exclusively, transduce. In the CNS for example, AAV8 and
AAV9 serotypes only infect neurons [161], while AAV5 vectors
have been reported to transduce both neurons and astrocytes
[162]. Selection of an appropriate serotype can therefore play an
important role in determining the cell type speciﬁcity of transgene
expression. Viral pseudotyping, in which one viral genome is pack-
aged into the wild-type or modiﬁed capsid of a second with prefer-
able tropism, has proven valuable in the design of recombinant
vectors with transduction properties speciﬁcally suited to a
researcher’s particular needs [160,163].
Serotype variety has also kept AAV vectors at the forefront of
strategies aimed at solving the so-called ‘‘volume obstacle’’ of gene
therapy translation [48]. Brieﬂy alluded to above, this term refers
to the increases in viral transduction volume that may be neces-
sary if therapeutically efﬁcacious vector delivery in rodents is to
be successfully translated to humans with brains many times lar-
ger. Increasing the spread of viral transduction through CNS tissue
will be especially important for treating more global neurologicalpathologies, including generalised epilepsies where small, spatially
restricted foci of hyperexcitability do not exist.
A number of different delivery strategies have exploited AAV
serotype variety to achieve such increases in viral transduction vol-
ume [15]. These include the use of serotypes that spread further
from the site of single stereotaxic injections (e.g. AAV9 and
AAV10) [164]; the delivery of serotypes amenable to transport
along neuronal pathways (e.g. AAV8 and AAV9) into brain nuclei
with divergent connectivity [165,166]; and vector injection
directly into cerebrospinal ﬂuid spaces (e.g. AAV4 and AAV5)
[162]. Another innovative approach involves intravenous adminis-
tration of serotypes that are BBB-permeable, such as AAV9 [167].
With respect to epilepsy, a very exciting advance has been the
combination of multiple capsid serotypes into chimeric AAV vec-
tors that selectively cross the seizure-compromised BBB [168].
5.1.3. Lentiviral vectors
Lentiviral vectors are also able to support long-lasting trans-
gene expression within post-mitotic neurons when appropriately
pseudotyped. They are currently the second most popular vector
for CNS gene therapy [149], and have been employed by a number
of studies investigating such treatments for epilepsy and pain
[43,44,58]. Relative to AAV vectors their advantages include a lar-
ger transgene capacity (9 kb) and a virtually non-existent
immunogenic proﬁle [169].
As with all members of the retrovirus family, lentiviruses natu-
rally integrate their DNA into the host cell’s genome, meaning the
risk of insertional mutagenesis with these vectors is relatively high.
This risk is ampliﬁed by the fact that several lentiviral subtypes,
such as HIV-1, display an integration location bias for transcrip-
tionally active genes [170]. Fortunately safety concerns regarding
genomic insertion have been largely mitigated by the design of
therapeutically efﬁcacious integration-deﬁcient lentiviral vectors
[171].
5.1.4. HSV vectors
HSV vectors are non-integrating, highly infectious viruses that
preferentially transduce neurons. They display a vast transgene
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combination of constructs, can be delivered in a single vector.
Despite these advantageous features, very few clinical trials for
CNS gene therapy have employed HSV vector delivery strategies
[149], perhaps because of their frequent inability to support
long-term transgene expression (but see ‘Promoters’ section below).
One application for which HSV vectors have proven very popu-
lar is transgene delivery to DRG neurons [94,121,122]. The unique
infection cycle of wild-type HSV explains why. HSV released from
infected skin or mucosal membranes invades the peripheral nerve
endings of DRG neurons, where the virus is retrogradely trans-
ported along the entire length of the peripheral axon branch to
the soma [172]. From a gene therapy perspective this retrograde
transport is ideal, as it abolishes the need to deliver vectors by
direct injection into relatively inaccessible ganglia. Instead, vectors
can be administered peripherally via intradermal inoculation,
ensuring only those afferents innervating the painful der-
matome(s) are transduced.
The retrograde transport of HSV vectors could be utilised cen-
trally to increase the spread of viral transduction through brain tis-
sue [173,174]. Such increases might contribute to a solution for the
aforementioned ‘‘volume obstacle’’ of gene therapy translation.
5.2. Promoters
An important decision in the design of gene therapies for epi-
lepsy and chronic pain is whether to suppress pathological hyper-
excitability directly by quelling the activity of excitatory principal
neurons, or indirectly by boosting the ﬁring of inhibitory interneu-
rons. Whichever approach is chosen, it is vital that the transgene
be expressed exclusively within the correct target neurons; acci-
dental suppression of ﬁring within inhibitory interneurons for
example would exacerbate rather than attenuate network hyper-
excitability. Although the choice of vector can determine cell type
speciﬁcity up to a point (e.g. in the distinction between glia and
neurons), reliably expressing a transgene within a predetermined
neuronal subtype almost always requires the use of cell type speci-
ﬁc promoter elements. For excitatory glutamatergic neurons the
element of choice is the CaMKIIa promoter, while for inhibitory
GABAergic neurons glutamate decarboxylase (isoform 65 or 67)
promoters are the most popular. Subpopulations of GABAergic
interneuron may also be selectively targeted using, for example,
PV or SST promoters.
The importance of driving transgene expression using cell type
speciﬁc promoters was demonstrated in early work by Haberman
and colleagues [133]. To suppress seizure-inducing hyperexcitabil-
ity via NMDAR knockdown, they used two independent non-cell
type speciﬁc promoters to drive expression of an NR1 antisense
sequence within neurons of the rat temporal cortex. When trans-
gene expression was driven using a CMV promoter, there was an
increase in the threshold for induction of focal seizures by electri-
cal stimulation. When the transgene was placed under the control
of a promoter suppressed by the presence of tetracycline (the
Tet-off promoter) however, seizure induction thresholds were sig-
niﬁcantly reduced. Immunohistochemical analysis demonstrated
that these opposite effects likely arose from NR1 antisense expres-
sion within distinct neuronal populations: excitatory principal
neurons with the CMV promoter and inhibitory interneurons with
the Tet-off construct.
This result highlights the inherent unpredictability of driving
transgene expression with strong non-cell type speciﬁc promoters.
But because many commercial viral vectors are supplied with such
elements, this strategy is often employed [44,133,134]. Even if cell
type speciﬁc expression can be achieved with a non-selective pro-
moter in rodent models however, it should not be assumed such
speciﬁcity will be replicated in humans. As a case in point,lentiviral delivery of a CMV-driven transgene to the rat motor cor-
tex leads to preferential expression within excitatory principal
neurons [44], yet a similar vector-promoter combination delivered
to the motor or visual cortices of NHPs elicits transgenic expression
almost exclusively within glial cells [164]. This difference high-
lights the importance of thoroughly characterising the cell type
speciﬁcity of transgene expression in multiple animal models
before a therapeutic vector progresses to clinical trials.
Promoters also play an important role in determining the long-
evity of transgene expression. For most gene therapy applications
long-term, even indeﬁnite, expression is preferable. The advan-
tages of such longevity are clear; the viral vector need only be
delivered once, increasing patient compliance and reducing the
risk of eliciting an immune response against repeat administra-
tions. In reality though long-term transgene expression is often dif-
ﬁcult to achieve. One reason for this is promoter silencing.
Although this phenomenon can occur with a number of therapeu-
tic vectors, those based on HSV are particularly susceptible [175].
Even strong constitutively active promoters such as CMV are
silenced within a few weeks of neuronal transduction [176–178].
HSV latency-active promoter 2 (LAP2) sequences may offer a solu-
tion to the problem. In wild-type HSV, the LAP2 element escapes
silencing while the virus lies dormant in infected neurons [179].
Vectors containing LAP2 promoters have been shown to support
CNS transgene expression lasting several months [180,181], and
it is thought they might be combined with cell type speciﬁc pro-
moters to achieve similar longevity in genetically identiﬁed neu-
ronal populations [150].
Despite the general preference for constitutive transgene
expression, the ability to terminate transcription in the event of
adverse side effects would be extremely attractive from a clinical
perspective. Such termination can be achieved with inducible pro-
moters. In these systems, exogenous pharmacological agents are
delivered to either activate or suppress promoter-driven transcrip-
tion [182]. Although inducible promoters have been incorporated
into vectors for gene therapy of chronic pain and epilepsy
[111,133], their progression to the clinic will be restricted by the
need for additional toxicology and tolerability testing of pharmaco-
logical components.
5.3. Regulatory, manufacturing and socioeconomic translational
hurdles
saw the ﬁrst human clinical trial for gene therapy [183].
22 years and hundreds of trials later, alipogene tiparvovec
(AAV1-LPLS447X; Glybera) became the ﬁrst such treatment to
achieve regulatory approval in the Western world [184,185]. This
extremely low conversion rate reﬂects the difﬁculties faced in
translating experimentally promising gene therapies to the clinic.
In this section we review these difﬁculties and offer tentative sug-
gestions for how they might be more successfully overcome.
Perhaps the greatest challenge to gene therapy translation
comes from regulatory agencies. In Europe and the USA, gene ther-
apy is subject to the same regulatory controls as traditional phar-
macotherapy [186]. As such, viral vector production must comply
with good manufacturing practice (GMP) guidelines, and therapeu-
tic efﬁcacy must be determined in multi-phase human clinical tri-
als. The academic research facilities in which most gene therapy
vectors are designed rarely have the infrastructure, ﬁnancial
resources or expertise necessary to meet these demands. There
therefore exists a strong argument for the creation of publically
subsidised or privately funded consortia that might shoulder the
responsibility [187].
Whether these calls for greater ﬁnancial collaboration are heard
or not, regulations could certainly be relaxed to allow consenting
patients faster access to promising but as-yet-unapproved gene
1630 A. Snowball, S. Schorge / FEBS Letters 589 (2015) 1620–1634therapies. Although extensive analyses of efﬁcacy, toxicology and
tolerability have their beneﬁts, for many patients suffering from
diseases refractory to traditional treatments gene therapy repre-
sents a last resort, and regulatory restrictions should take this into
account if individuals are willing to accept the inherent risks of an
incompletely tested therapeutic agent [186]. With respect to toxi-
cology and tolerability, academics responsible for vector design
could speed up translation by employing vector backbones that
have already been characterised [188].
It is reasonable to assume that the clinical translation of gene
therapy might beneﬁt from greater pharmaceutical involvement
in vector production and testing. Thus far contribution from these
companies has been minimal, possibly due to concerns regarding
the small ﬁnancial returns on offer. Viral vector production would
necessitate infrastructural updates to manufacturing and storage
facilities, and the cost of these would be difﬁcult to recoup from
sales of biotherapies designed to be administered just once to (ini-
tially) small populations of patients. Moreover, pharmaceutical
companies are unlikely to willingly sacriﬁce proﬁt by introducing
market competition for their highest-earning pharmacological
agents.
An additional concern for gene therapy translation is public
opinion of the approach. Adverse outcomes from early clinical tri-
als [12,13] continue to cast a shadow in the minds of patients and
clinicians alike. From the clinician’s perspective, the perceived
complexity of genetic approaches relative to established pharma-
cotherapy may initially limit clinical usage. This complexity issue
will be particularly relevant for combination therapies such as
chemogenetics and optogenetics [59].
Despite the many translational hurdles gene therapy faces, the
technique has recovered from early setbacks to demonstrate gen-
uine promise for the treatment of a wide variety of disorders.
The growing list of successful human trials [16] will continue to
assuage regulatory, ﬁnancial and social concerns surrounding the
approach, generating momentum for the translation of many more
therapeutic vectors.
6. Conclusions and perspectives
Chronic pain and epilepsy are ideally suited to therapeutic
interventions targeted at suppressing neuronal hyperexcitability.
The manipulation of ion channel expression using viral gene ther-
apy represents one such intervention that is already progressing
from proof-of-principle research to the clinic.
From a translational perspective the most straightforward ion
channel targets are those that regulate excitability endogenously.
While optogenetic and chemogenetic approaches display promise
in an experimental setting, the added complexity of activation by
exogenous stimuli will inevitably slow their clinical development.
Conversely, for the genetic manipulation of endogenous protein
expression there have already been numerous successful clinical
trials for various disorders and one approved treatment. To identify
similar gene therapy strategies capable of treating chronic pain and
epilepsy, further preclinical testing will be necessary to guide
rational selection of appropriate transgenes. So far these have con-
sisted primarily of ion channel cDNAs or shRNAs targeting ion
channel genes. However, exciting recent advances in gene-editing
technologies such as the CRISPR-Cas9 system could soon open
the door to an entirely novel set of transgenic tools capable of
not only upregulating or downregulating ion channel expression,
but also repairing disease-causing channel mutations.
To speed up clinical translation, therapeutic transgenes should
be packaged into vectors already characterised for toxicology and
tolerability within human patients. As the gold standard for deliv-
ery of exogenous genetic material, viral vectors have formed thecentral focus of this review. It will be interesting to see whether
emerging technologies such as nanoparticles can overcome the
established bias against non-viral delivery strategies. Whatever
strategy is used, the performance of therapeutic vectors within
clinical trials for chronic pain and epilepsy will depend heavily
on the degree to which regulatory, ﬁnancial and social concerns
surrounding gene therapy are addressed, and ideally, relaxed.
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